Methods and means of generating il-17 associated antitumor effector cells by inhibition of nr2f6 inhibition
AssigneeRegen Biopharma, Inc.
InventorsDavid KOOS, Thomas ICHIM, Santosh KESARI
Life of this patent
Estimating the term…
Abstract
Disclosed are means, methods, and compositions of matter useful for generation of cancer inhibitory effector cells producing interleukin-17 (IL-17). In one embodiment a cellular population is obtained, said cellular population is exposed to agents capable of inhibiting NR2F6, whereby said inhibition of NR2F6 results in upregulation of IL-17 production, said upregulation of IL-17 production associated with acquisition of anti-tumor activity.
Claims18
A cellular population capable of inhibiting cancer, said cellular population modulated to express lower levels of NR2F6 as compared to non-manipulated cellular population, wherein said lower level of NR2F6 is associated with augmentation of IL-17 production, wherein said IL-17 production is associated with reduction of tumor activity.
A method of generating a tumor killing population of cells comprising admixing NR2F6 inhibited T cells with monocytes, allowing said T cells to induce monocyte activation and said monocytes to feedback activatory signals to said T cells.
Dependencies are inferred from the claim text.